You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The Tokyo-based firm said it will use the funding to support prototyping and commercialization of its mass spectrometry and optical spectroscopy instruments.
The firm said it will use the funding to invest in research and development that will improve upon its deep shotgun metagenomic sequencing technology.
MyCartis said that the new company, Antelope Dx, is developing a home test to diagnose Chlamydia trachomatis and Neisseria gonorrhea.
The financing, led by Accelerated Digital Ventures, will go toward the development of 20 tests targeted at cancers and dementias.
The German firm has developed a PCR technology that rapidly regulates temperature with so-called microcyclers diffused in the master mix solution.
Formerly known as Diassess, the Emeryville, California-based startup will use the funding to finance regulatory clearances and early commercialization.
Denka now owns 33.4 percent of PlexBio's shares. PlexBio will use the financing for operations and product development.
The firm said that the new funds will enable it to build on the continued commercial expansion of its first product, PredictSure IBD, in the coming months.
The company recently launched Prompt Prostate Genetic Score, a lab-developed test to track a man's genetic predisposition to prostate cancer.
The French company develops software solutions for digital pathology, including software for microscopic and macroscopic image management.